JP2000319190A - Prophylactic and improving agent for obesity - Google Patents
Prophylactic and improving agent for obesityInfo
- Publication number
- JP2000319190A JP2000319190A JP11127921A JP12792199A JP2000319190A JP 2000319190 A JP2000319190 A JP 2000319190A JP 11127921 A JP11127921 A JP 11127921A JP 12792199 A JP12792199 A JP 12792199A JP 2000319190 A JP2000319190 A JP 2000319190A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- aloe
- obesity
- preventing
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する分野】本発明は、肥満の予防及び改善作
用を有する肥満の予防改善剤、その製法及び肥満の予防
改善剤を含む医薬品、食品、飲料などに関するものであ
る。The present invention relates to a prophylactic and / or ameliorating agent for obesity having an effect of preventing and / or ameliorating obesity, a method for producing the same, and pharmaceuticals, foods and drinks containing the agent for preventing and / or improving obesity.
【０００２】[0002]
【従来の技術】近年、生活水準の向上、欧米型の食生活
への変化、あるいは運動不足傾向の増加に伴い、肥満者
の増加や若年化が顕著になってきている。一般に肥満
は、カロリーの過剰摂取により引き起こされるため、肥
満の予防や治療には摂取カロリーを低減させる方法が用
いられている。通常、摂取カロリーを低減させるには食
事療法が行われるが、継続して行うことが非常に困難な
場合が多く、過度の食事制限により、栄養障害や拒食症
に陥ることもあった。2. Description of the Related Art In recent years, the number of obese people and the number of young people have become remarkable with the improvement of living standards, the shift to a Western-style diet, and the tendency of lack of exercise. In general, obesity is caused by excessive intake of calories, and a method of reducing calorie intake is used for prevention and treatment of obesity. Usually, dietary treatment is performed to reduce the calorie intake, but it is often extremely difficult to continue the dietary treatment, and excessive dietary restriction sometimes causes nutritional disorders and anorexia nervosa.
【０００３】このような観点から、肥満の治療に薬物を
用いることが検討されている。例えば、中枢系に作用し
て食欲を抑制する薬剤や、小腸の微絨毛に局在する二糖
分解酵素を阻害し、食後の血糖値の急上昇を抑制する薬
剤などが試みられている。しかしながら、薬物の長期間
の投与や全身の臓器に達した場合の安全性については、
未だ問題が残されている。そのため、安全面を考慮し
て、天然物由来の物質を肥満予防に応用した例も報告さ
れてはいるものの効果の面で必ずしも満足のいくもので
はなかった。[0003] From such a viewpoint, the use of drugs for treating obesity has been studied. For example, drugs that act on the central system to suppress appetite and drugs that inhibit disaccharide degrading enzymes localized in the microvilli of the small intestine and suppress a sharp rise in blood glucose level after eating have been tried. However, regarding long-term drug administration and safety when reaching systemic organs,
There are still problems. For this reason, in consideration of safety, there has been reported an example in which a substance derived from a natural product is applied to the prevention of obesity, but the effect was not always satisfactory.
【０００４】[0004]
【発明が解決しようとする課題】上記のような従来の肥
満予防改善剤は、効果及び安全面で問題点があるため、
植物由来の物質で、体内で有効に作用することの可能
な、つまり、生体にとって安全性が高く、効果的な肥満
予防改善剤の出現が望まれていた。そこで本発明は、天
然物に由来し、長期投与によっても副作用がなく、効果
的な肥満予防改善剤を提供することにある。The above-mentioned conventional obesity prevention / amelioration agents have problems in terms of efficacy and safety.
There has been a demand for an effective agent for preventing and improving obesity, which is a plant-derived substance that can effectively act in the body, that is, is highly safe for the living body. Therefore, an object of the present invention is to provide an effective agent for preventing and improving obesity, which is derived from natural products and has no side effects even after long-term administration.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、古くから
民間薬として利用されてきたアロエに注目し、体重増加
の抑制作用を動物実験を用いて検討した。その結果、ア
ロエの抽出物に肥満の予防及び改善効果があることを見
い出し、本発明を完成するに至った。尚、本発明で用い
る肥満の予防改善剤とは、体重増加を伴う肥満の進行を
抑制し、過度の食事制限を必要とすることなく、標準的
な体重の維持に効果的であることを意味する。Means for Solving the Problems The present inventors have paid attention to aloe, which has been used as a folk medicine for a long time, and studied the inhibitory action of weight gain using animal experiments. As a result, they found that the aloe extract had an effect of preventing and improving obesity, and completed the present invention. The agent for preventing or improving obesity used in the present invention means that it is effective for suppressing the progression of obesity accompanied by weight gain and maintaining a standard weight without requiring excessive dietary restriction. I do.
【０００６】本発明で用いるアロエとしては、キダチア
ロエ（学名：Aloe arborescens Miller）、アロエベラ
（学名：Aloe barbadensis Miller）、ケープアロエ
（学名：Aloe ferox Miller）、アロエアンドンゲンシ
ス（学名：Aloe andongensis Miller）などが挙げられ
る。中でも、キダチアロエ、アロエベラがより好まし
い。The aloe used in the present invention includes aloe aloe arborescens Miller (scientific name: Aloe barbadensis Miller), aloe barbadensis miller (scientific name), Cape aloe (scientific name: Aloe ferox Miller), and aloe andongensis Miller (scientific name: Aloe andongensis Miller). And the like. Among them, kidachi aloe and aloe vera are more preferred.
【０００７】本発明に用いられるアロエの抽出物は、上
記アロエの葉、果肉、果皮、花、茎、根などの植物体の
一部又は全草から抽出されたものである。好ましくは、
有効成分の含有量において、果肉、果皮を抽出したもの
が良い。更に具体例としては、以下の方法で有効成分を
抽出、濃縮することができる。[0007] The extract of aloe used in the present invention is extracted from a part or whole of a plant such as the aloe leaf, pulp, pericarp, flower, stem and root. Preferably,
In terms of the content of the active ingredient, those obtained by extracting pulp and pericarp are preferable. As a more specific example, the active ingredient can be extracted and concentrated by the following method.
【０００８】アロエの果肉、果皮の搾汁を濃縮して抽出
物（以下、搾汁抽出物と呼ぶ）を得ることができる。ま
た、アロエの果肉、果皮を溶媒で抽出し、抽出液を濃縮
し、抽出物（以下、溶媒抽出物と呼ぶ）を得ることがで
きる。これらの搾汁抽出物及び溶媒抽出物は市販品を使
用することができる。更には、この搾汁抽出物又は溶媒
抽出物を水と酢酸エチル又は水とブタノールで分配抽出
して得られた酢酸エチル又はブタノール層を濃縮するこ
とにより、本発明のアロエの有効成分が濃縮された抽出
物（酢酸エチル又はブタノール分配抽出物）を得ること
ができる。[0008] An extract (hereinafter referred to as a squeezed extract) can be obtained by concentrating the squeezed juice of the aloe pulp and pericarp. Further, the flesh and pericarp of aloe can be extracted with a solvent, and the extract can be concentrated to obtain an extract (hereinafter, referred to as a solvent extract). Commercial products can be used for these juice extracts and solvent extracts. Furthermore, the active ingredient of aloe of the present invention is concentrated by concentrating the ethyl acetate or butanol layer obtained by partitioning and extracting the squeezed extract or the solvent extract with water and ethyl acetate or with water and butanol. Extract (ethyl acetate or butanol partitioned extract) can be obtained.
【０００９】上記溶媒抽出に用いる溶媒としては、本発
明の肥満予防改善効果を示す成分が抽出される溶媒であ
れば何でも良いが、例えば、水、低級アルコール類（メ
タノール、エタノール、プロパノール、ブタノールな
ど）、ケトン類（アセトン、メチルエチルケトンな
ど）、アセトニトリル、エステル類（酢酸エチル、酢酸
ブチルなど）、炭化水素類（ヘキサン、ヘプタン、流動
パラフィンなど）、エーテル類（エチルエーテル、テト
ラヒドロフラン、プロピルエーテルなど）、クロロホル
ム、ジクロロメタンなどが挙げられる。好ましくは、
水、上記低級アルコール及びケトンなどの極性溶媒が良
い。これらの溶媒は１種でも２種以上を混合して用いて
も良い。The solvent used in the solvent extraction may be any solvent as long as it is a solvent from which the components of the present invention that exhibit the effect of preventing and improving obesity can be extracted. For example, water, lower alcohols (methanol, ethanol, propanol, butanol, etc.) ), Ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether, etc.), Chloroform, dichloromethane and the like can be mentioned. Preferably,
Polar solvents such as water, the lower alcohols and ketones described above are preferred. These solvents may be used alone or in combination of two or more.
【００１０】酢酸エチル及びブタノールによる分配抽出
は次の様に行われる。搾汁抽出物又は溶媒抽出物に水を
加え、水溶液とする。加える水の量は搾汁抽出物又は溶
媒抽出物乾固物に換算して、１０〜２００倍重量が好ま
しい。この水溶液に対して、０．５〜２倍容量、好まし
くは１倍容量の酢酸エチル又はブタノールを加えて振と
う抽出を行う。次いで、得られた酢酸エチル又はブタノ
ール層を濃縮乾固させることにより、酢酸エチル又はブ
タノール分配抽出物を得ることができる。また、残りの
水層に酢酸エチル又はブタノールを加えて、同様にして
２〜５回繰り返し分配抽出しても良い。本発明で行う濃
縮は、成分の分解が抑制される点において、減圧下、40
℃以下で行うのが好ましい。[0010] Partition extraction with ethyl acetate and butanol is performed as follows. Water is added to the juice extract or the solvent extract to make an aqueous solution. The amount of water to be added is preferably 10 to 200 times the weight in terms of the squeezed extract or the solvent extract to dryness. To this aqueous solution, 0.5 to 2 volumes, preferably 1 volume, of ethyl acetate or butanol is added and shake extraction is performed. Then, the obtained ethyl acetate or butanol layer is concentrated to dryness to obtain an ethyl acetate or butanol partition extract. Alternatively, ethyl acetate or butanol may be added to the remaining aqueous layer, and the extraction may be repeated 2 to 5 times in the same manner. The concentration performed in the present invention is performed under reduced pressure at a point that decomposition of components is suppressed.
It is preferably carried out at a temperature of not more than ° C.
【００１１】上記分画抽出物は、更なる精製を行うこと
ができ、シリカゲルを用いた順相又はODSなどを用いた
逆相クロマトグラフィー、ゲル濾過クロマトグラフィー
あるいはイオン交換クロマトグラフィーなどの一般公知
の分離法で精製を行うことにより、有効成分を更に濃縮
することができる。The above-mentioned fractionated extract can be further purified, and is generally known in the art, such as normal phase using silica gel or reverse phase chromatography using ODS, gel filtration chromatography or ion exchange chromatography. By purifying by a separation method, the active ingredient can be further concentrated.
【００１２】また、上記アロエの搾汁抽出物、溶媒抽出
物及び分配抽出物は、抽出した溶液のまま用いても良
く、必要に応じて濃縮、希釈、濾過などの処理をしても
良い。更には、抽出した溶液を濃縮乾固、噴霧乾燥、凍
結乾燥などの処理を行い、乾燥物として用いても良い。The squeezed extract, solvent extract and distribution extract of the aloe may be used as they are as extracted solutions, or may be subjected to treatment such as concentration, dilution and filtration as required. Further, the extracted solution may be subjected to treatments such as concentration and drying, spray drying, and freeze drying to be used as a dried product.
【００１３】本発明の肥満予防改善剤は、肥満の治療は
もとより、予防の目的で、医薬、食品、飲料などの形態
で摂取し、保健上、利用価値の高い成分である。また、
肥満に付随して起こる成人病の予防、改善、治療にも有
効である。本発明の肥満の予防改善剤は単独で用いる
他、一般的な賦形剤、安定剤、保存剤、結合剤、崩壊
剤、その他の肥満予防改善剤などの適当な添加物を配合
することができる。剤形としては通常、散剤、錠剤、坐
剤、乳剤、カプセル剤、顆粒剤、液剤（チンキ剤、流エ
キス剤、酒精剤、懸濁剤、リモナーデ剤などを含む）な
どが挙げられる。食品としては、肥満予防及び肥満に付
随して起こる成人病予防の目的で、その食品としての機
能を十分に生かすべく、特定保健用食品、病者用食品な
どの特別用途食品や、健康食品などに配合できる。ま
た、その他の食品においても、肥満予防を目的として配
合できる。例えば、使用する賦形剤は、食品衛生法など
の食品規定に記載される食品原料を用いることができ
る。上記医薬、食品への添加量としては、0.001〜20重
量％が好ましく、特に0.01〜10重量％が好ましい。The agent for preventing and improving obesity of the present invention is a component which is ingested in the form of medicines, foods, beverages and the like for the purpose of treating obesity as well as for preventing it, and has high utility value in health. Also,
It is also effective in preventing, ameliorating, and treating adult diseases associated with obesity. The agent for preventing or improving obesity of the present invention may be used alone, or may be mixed with appropriate additives such as general excipients, stabilizers, preservatives, binders, disintegrants, and other agents for preventing or improving obesity. it can. Dosage forms usually include powders, tablets, suppositories, emulsions, capsules, granules, liquids (including tinctures, liquid extracts, alcoholic beverages, suspensions, limonades, etc.) and the like. As foods, for the purpose of preventing obesity and the prevention of adult diseases associated with obesity, special use foods such as foods for specified health use, foods for the sick, health foods, etc. Can be blended. In addition, other foods can be blended for the purpose of preventing obesity. For example, as an excipient to be used, food raw materials described in food regulations such as the Food Sanitation Law can be used. The amount added to the above medicines and foods is preferably 0.001 to 20% by weight, particularly preferably 0.01 to 10% by weight.
【００１４】[0014]
【実施例】次に本発明を詳細に説明するため、実施例と
して本発明に用いる抽出物の製造例、本発明の処方例及
び実験例を挙げるが、本発明はこれに限定されるもので
はない。実施例に示す配合量の部とは重量部を示す。EXAMPLES In order to explain the present invention in detail, examples of the production of the extract used in the present invention, prescription examples of the present invention and experimental examples will be given below, but the present invention is not limited to these examples. Absent. The parts of the amounts shown in the examples are parts by weight.
【００１５】製造例１ キダチアロエのエタノール抽出
物 乾燥したキダチアロエ1 kgをエタノール10 Lで１週間室
温で抽出し、得られた抽出液を濾過後、減圧下濃縮し、
乾燥させてキダチアロエのエタノール抽出物を148 g得
た。Production Example 1 Ethanol Extract of Kidachiaroe 1 kg of dried Kidachialoe was extracted with 10 L of ethanol at room temperature for 1 week, and the obtained extract was filtered and concentrated under reduced pressure.
It was dried to obtain 148 g of ethanol extract of Kidachi aloe.
【００１６】製造例２ アロエベラの50％含水エタノー
ル抽出物 乾燥したアロエベラ1 kgを50％含水エタノール10 Lで１
週間室温で抽出し、得られた抽出液を濾過後、減圧下濃
縮し、乾燥させてアロエベラの50％含水エタノール抽出
物を173 g得た。Preparation Example 2 50% aqueous ethanol extract of aloe vera 1 kg of dried aloe vera was extracted with 10 L of 50% aqueous ethanol.
After extraction at room temperature for a week, the obtained extract was filtered, concentrated under reduced pressure, and dried to obtain 173 g of a 50% aqueous ethanol extract of aloe vera.
【００１７】製造例３ キダチアロエの熱水抽出物の酢
酸エチル分配抽出物 市販のキダチアロエの熱水抽出物（日本粉末薬品製）20
0 gを水20 Lに溶解し、酢酸エチル20 Lを加えて振とう
し、酢酸エチル層を分取した。残りの水層に対して、同
様に酢酸エチルによる抽出を３回行った。酢酸エチル層
を合わせ、減圧下溶媒を留去し、乾燥させてキダチアロ
エの熱水抽出物の酢酸エチル分配抽出物を2.1 g得た。Production Example 3 Partition Extract of Ethyl Acetate from Hot Water Extract of Kidachi Aloe Commercial Hot Water Extract of Kidachi Aloe (Nippon Powder Chemical Co., Ltd.) 20
0 g was dissolved in 20 L of water, 20 L of ethyl acetate was added, and the mixture was shaken to separate the ethyl acetate layer. The remaining aqueous layer was similarly extracted three times with ethyl acetate. The ethyl acetate layers were combined, the solvent was distilled off under reduced pressure, and the residue was dried to obtain 2.1 g of an ethyl acetate partitioned extract of a hot water extract of Kidachialoe.
【００１８】製造例４ キダチアロエの熱水抽出物のブ
タノール分配抽出物 市販のキダチアロエの熱水抽出物（日本粉末薬品製）20
0 gを水20 Lに溶解し、ブタノール20 Lを加えて振とう
し、ブタノール層を分取した。残りの水層に対して、同
様にブタノールによる抽出を３回行った。ブタノール層
を合わせ、減圧下溶媒を留去し、乾燥させてキダチアロ
エの熱水抽出物のブタノール分配抽出物を16.0 g得た。Production Example 4 Partitioned butanol extract of hot water extract of Kidachi aloe Hot water extract of commercially available Kidachi aloe (Nippon Powder Chemical Co., Ltd.) 20
0 g was dissolved in 20 L of water, 20 L of butanol was added, and the mixture was shaken to separate the butanol layer. The remaining aqueous layer was similarly extracted three times with butanol. The butanol layers were combined, the solvent was distilled off under reduced pressure, and the residue was dried to obtain 16.0 g of a butanol-partitioned extract of a hot water extract of Kidachialoe.
【００１９】 実施例１ 散剤１ 処方 配合量 1. キダチアロエのエタノール抽出物（製造例１） 2.0部 2. 乾燥コーンスターチ 38.0 3. 微結晶セルロース 60.0 [ 製法 ]成分１〜3を混合研和し、散剤とする。Example 1 Powder 1 Formulation Compounding amount 1. Ethanol extract of Kidachi aloe (Preparation Example 1) 2.0 parts 2. Dried corn starch 38.0 3. Microcrystalline cellulose 60.0 [Production method] And
【００２０】実施例２ 散剤２ 実施例１において、キダチアロエのエタノール抽出物を
アロエベラの50％含水エタノール抽出物（製造例２）に
置き換えたものを散剤２とした。Example 2 Powder 2 Powder 2 was prepared by replacing the ethanol extract of Kidachi aloe in Example 1 with a 50% aqueous ethanol extract of aloe vera (Preparation Example 2).
【００２１】実施例３ 散剤３ 実施例１において、キダチアロエのエタノール抽出物を
キダチアロエの熱水抽出物の酢酸エチル分配抽出物（製
造例３）に置き換えたものを散剤３とした。Example 3 Powder 3 Powder 3 was prepared in the same manner as in Example 1 except that the ethanol extract of Kidachialoe was replaced with an ethyl acetate distribution extract of hot water extract of Kidachiaroe (Production Example 3).
【００２２】実施例４ 散剤４ 実施例１において、キダチアロエのエタノール抽出物を
キダチアロエの熱水抽出物のブタノール分配抽出物（製
造例４）に置き換えたものを散剤４とした。Example 4 Powder 4 Powder 4 was prepared in the same manner as in Example 1 except that the ethanol extract of Kidachialoe was replaced with a butanol-distributed extract of hot water extract of Kidachiaroe (Production Example 4).
【００２３】比較例１ 散剤Ａ（アロエの抽出物未配合
の散剤） 実施例１において、キダチアロエのエタノール抽出物を
乾燥コーンスターチに置き換えたものを散剤Ａとした。Comparative Example 1 Powder A (Powder without Aloe extract) Powder A prepared by replacing ethanol extract of Kidachi aloe with dried corn starch in Example 1 was used.
【００２４】 実施例５ 錠剤 処方 配合量 1. キダチアロエの熱水抽出物の酢酸エチル分配抽出物（製造例３） 5.0部 2. 乾燥コーンスターチ 25.0 3. カルボキシメチルセルロースカルシウム 20.0 4. 微結晶セルロース 40.0 5. ポリビニルピロリドン 7.0 6. タルク 3.0 [ 製法 ]成分1〜4を混合し、次いで成分5の水溶液を結
合剤として加えて顆粒成形する。成形した顆粒に成分6
を加えて打錠する。１錠0.52 gとする。Example 5 Tablet Formulation Formulation Amount 1. Ethyl acetate distribution extract of hot water extract of Kidachi aloe (Production Example 3) 5.0 parts 2. Dried corn starch 25.0 3. Carboxymethylcellulose calcium 20.0 4. Microcrystalline cellulose 40.0 5. Polyvinylpyrrolidone 7.0 6. Talc 3.0 [Preparation] Components 1 to 4 are mixed, and an aqueous solution of component 5 is added as a binder to form granules. Ingredient 6 in molded granules
And tableting. 0.52 g per tablet.
【００２５】 実施例６ 錠菓 処方 配合量 1. キダチアロエの熱水抽出物のブタノール分配抽出物（製造例４） 2.0部 2. 乾燥コーンスターチ 50.0 3. エリスリトール 40.0 4. クエン酸 5.0 5. ショ糖脂肪酸エステル 3.0 6. 香料 適量 7. 水 適量 [ 製法 ]成分1〜4及び7を混合し、顆粒成形する。成形
した顆粒に成分5及び6を加えて打錠する。１粒1.0 gと
する。Example 6 Tablet Confectionery Prescription Formulation Amount 1. Butanol-partitioned extract of hot water extract of Kidachi aloe (Production Example 4) 2.0 parts 2. Dried corn starch 50.0 3. Erythritol 40.0 4. Citric acid 5.0 5. Sucrose fatty acid Ester 3.0 6. Appropriate amount of flavoring agent 7. Appropriate amount of water [Production method] Mix components 1-4 and 7 and granulate. Ingredients 5 and 6 are added to the formed granules and tableted. One grain is 1.0 g.
【００２６】 実施例７ 飲料 処方 配合量 1. アロエベラの50％含水エタノール抽出物（製造例２） 1.0部 2. ステビア 0.05 3. リンゴ酸 5.0 4. 香料 0.1 5. 水にて全量を100とする [ 製法 ]成分2及び3を少量の水に溶解する。次いで、成
分1及び4、5を加えて混合する。Example 7 Beverage Formulation Compounding amount 1. Aloe vera 50% aqueous ethanol extract (Preparation Example 2) 1.0 part 2. Stevia 0.05 3. Malic acid 5.0 4. Fragrance 0.1 5. Adjust the total amount to 100 with water [Preparation method] Dissolve components 2 and 3 in a small amount of water. Then, components 1 and 4, 5 are added and mixed.
【００２７】次に、本発明を詳細に説明するため、実験
例を挙げる。Next, experimental examples will be described in order to explain the present invention in detail.
【００２８】実験例 ラット体重増加抑制試験 実験には１４週令Wistar系雄性ラットを１群６匹として
使用した。市販の飼料（オリエンタル酵母工業製：マウ
ス・ラット飼育用−MF）に、キダチアロエ及びアロエベ
ラの抽出物を配合した本発明の散剤（実施例１〜４）を
それぞれ5.0％添加した飼料を調製し、自由に摂取させ
た。また、比較としてアロエの抽出物未配合の散剤Ａ
（比較例１）を5.0％添加した飼料を調製し、自由に摂
取させた（対照群）。散剤添加飼料による飼育開始から
試験終了の２８日目まで、ラットの体重と飼料の摂取量
を毎日測定した。また、試験終了時に解剖を行い、組織
検査と血液検査を行った。Experimental Example Rat Weight Gain Inhibition Test In the experiment, 14-week-old male Wistar rats were used in groups of 6 rats. A commercial feed (manufactured by Oriental Yeast Co., Ltd .: mouse / rat breeding -MF) was added to the powder of the present invention (Examples 1 to 4) in which an extract of Kidachi aloe and aloe vera were combined to prepare a feed in which 5.0% was added. They were allowed free access. As a comparison, powder A containing no aloe extract was used.
A feed containing 5.0% of (Comparative Example 1) was prepared and fed freely (control group). From the start of feeding on the powder-added feed to the 28th day of the end of the test, the body weight and feed intake of the rats were measured daily. At the end of the test, dissection was performed, and histological and blood tests were performed.
【００２９】表１に、飼育開始から７、１４、２１及び
２８日後の体重の増加量と、対照群と比較したときの増
加抑制率及び1日当たりの飼料の摂取量の平均値を示
す。本発明の散剤を添加した飼料で飼育した群は、対照
群と比較して体重増加量が少なく、アロエの抽出物には
十分な体重増加抑制効果がみられた。飼料の摂取量には
有意な差異は認められないため、この体重増加量の差は
飼料の摂取量によるものではないと言える。アロエの抽
出物添加の群における体重増加の過程で、飼育初期の段
階の体重の落ち込みは観察されず、また、実験終了時の
解剖の結果から、組織学的にも血液学的にも異常は認め
られなかったことから、アロエの抽出物は一般的健康状
態には影響を与えることなく、体重増加の抑制に効果的
であることが示された。Table 1 shows the increase in body weight 7, 14, 21 and 28 days after the start of breeding, the increase suppression rate as compared with the control group, and the average value of feed intake per day. In the group bred with the feed to which the powder of the present invention was added, the amount of weight gain was smaller than that of the control group, and the aloe extract showed a sufficient weight gain suppressing effect. There is no significant difference in feed intake, so it can be said that this difference in weight gain is not due to feed intake. In the process of weight gain in the aloe extract-added group, no decrease in body weight was observed in the early stage of rearing, and the results of the dissection at the end of the experiment showed no abnormalities in histology or hematology. The lack of evidence indicated that the aloe extract was effective in controlling weight gain without affecting general health.
【００３０】 [0030]
【００３１】実施例５、６の錠剤及び錠菓については、
乳鉢で粉末化した試料を用いて散剤と同様の試験を行っ
た。また、実施例７の飲料については、試料3 mLを胃ゾ
ンデを用いて１日３回経口投与し、同様に体重増加抑制
に対する効果を調べた。その結果、実施例５〜７につい
ても同様の体重増加抑制効果が認められた。For the tablets and confections of Examples 5 and 6,
A test similar to the powder was performed using a sample powdered in a mortar. In addition, with respect to the beverage of Example 7, 3 mL of the sample was orally administered three times a day using a gastric probe, and the effect on weight gain suppression was similarly examined. As a result, the same effect of suppressing weight gain was observed for Examples 5 to 7.
【００３２】[0032]
【発明の効果】本発明により、アロエの抽出物が体重増
加抑制に対して効果的であることを見い出した。これら
を有効成分として配合した肥満の予防改善剤は長期間継
続投与しても安全であり、肥満の予防改善効果に優れて
いた。According to the present invention, it has been found that an aloe extract is effective for suppressing weight gain. The prophylactic / ameliorating agent for obesity containing these as active ingredients was safe even when administered continuously for a long period of time, and was excellent in the effect of preventing / improving obesity.
───────────────────────────────────────────────────── フロントページの続き Ｆターム(参考） 4B017 LC03 LE10 LG15 LK06 LK07 LL09 LP01 LP02 LP03 4B018 LB01 LB08 LE01 MD08 MD65 ME01 MF01 MF06 4C088 AB86 AC05 BA08 BA09 BA10 CA03 CA11 MA52 NA14 ZA70 ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4B017 LC03 LE10 LG15 LK06 LK07 LL09 LP01 LP02 LP03 4B018 LB01 LB08 LE01 MD08 MD65 ME01 MF01 MF06 4C088 AB86 AC05 BA08 BA09 BA10 CA03 CA11 MA52 NA14 ZA70
Claims (6)
することを特徴とする肥満の予防改善剤。1. An agent for preventing and improving obesity, which comprises an aloe extract as an active ingredient.
であることを特徴とする請求項１記載の肥満の予防改善
剤。2. The agent for preventing and improving obesity according to claim 1, wherein the aloe is almond aloe and aloe vera.
特徴とする請求項１又は２記載の肥満の予防改善剤。3. The agent for preventing and improving obesity according to claim 1, wherein the extract is a polar solvent extract.
媒抽出物の水溶液を酢酸エチル又はブタノールで分配抽
出し、濃縮乾固した抽出物であることを特徴とする請求
項１〜３のいずれか１項記載の肥満の予防改善剤。4. The extract according to claim 1, wherein the extract is an extract obtained by partitioning and extracting an aqueous solution of an aloe squeezed extract or a solvent extract with ethyl acetate or butanol and concentrating to dryness. The agent for preventing or improving obesity according to any one of the above.
満の予防改善剤を含有することを特徴とする肥満の予防
改善用食品。5. A food for preventing and improving obesity, comprising the agent for preventing and improving obesity according to any one of claims 1 to 4.
水溶液を酢酸エチル又はブタノールで分配抽出し、濃縮
乾固することを特徴とする肥満の予防改善剤の製法。6. A method for producing an agent for preventing and improving obesity, which comprises partitioning and extracting an aqueous solution of a squeezed extract or a solvent extract of aloe with ethyl acetate or butanol and concentrating to dryness.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12792199A JP4499209B2 (en) | 1999-05-10 | 1999-05-10 | Obesity prevention and improvement agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12792199A JP4499209B2 (en) | 1999-05-10 | 1999-05-10 | Obesity prevention and improvement agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000319190A true JP2000319190A (en) | 2000-11-21 |
| JP4499209B2 JP4499209B2 (en) | 2010-07-07 |
Family
ID=14971938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12792199A Expired - Fee Related JP4499209B2 (en) | 1999-05-10 | 1999-05-10 | Obesity prevention and improvement agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4499209B2 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241293A (en) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| WO2007034851A1 (en) * | 2005-09-22 | 2007-03-29 | Morinaga Milk Industry Co., Ltd. | Visceral fat accumulation inhibitor |
| WO2007043302A1 (en) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Agent for amelioration of insulin resistance |
| WO2007043305A1 (en) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Agent for amelioration of insulin resistance |
| WO2007043306A1 (en) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Agent for amelioration of insulin resistance |
| WO2007043294A1 (en) * | 2005-09-22 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Visceral fat accumulation inhibitor |
| WO2007060911A1 (en) | 2005-11-25 | 2007-05-31 | Morinaga Milk Industry Co., Ltd. | Aloe vera extract, process for production of aloe vera extract, and ameliorating agent for hyperglycemia |
| US20100240632A1 (en) * | 2004-03-31 | 2010-09-23 | Morinaga Milk Industry Co., Ltd. | Drug for improving hyperglycemia |
| US7867525B2 (en) * | 2002-08-14 | 2011-01-11 | Bionutrigen Co., Ltd. | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
| WO2020159038A1 (en) * | 2019-01-30 | 2020-08-06 | (주)메이준생활건강 | Pharmaceutical composition for preventing or treating obesity, containing extract of aloe vera, pseudocydonia sinensis and zea mays linne as active ingredient |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112451516A (en) * | 2020-12-24 | 2021-03-09 | 海南医学院 | Application of aloesin in preparation of products related to obesity prevention or treatment |
-
1999
- 1999-05-10 JP JP12792199A patent/JP4499209B2/en not_active Expired - Fee Related
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241293A (en) * | 2001-02-13 | 2002-08-28 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| US7867525B2 (en) * | 2002-08-14 | 2011-01-11 | Bionutrigen Co., Ltd. | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
| US8338403B2 (en) * | 2004-03-31 | 2012-12-25 | Morinaga Milk Industry Co., Ltd. | Drug for improving hyperglycemia |
| US20100240632A1 (en) * | 2004-03-31 | 2010-09-23 | Morinaga Milk Industry Co., Ltd. | Drug for improving hyperglycemia |
| US8093233B2 (en) | 2005-09-22 | 2012-01-10 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting visceral fat accumulation |
| WO2007043294A1 (en) * | 2005-09-22 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Visceral fat accumulation inhibitor |
| US8518924B2 (en) | 2005-09-22 | 2013-08-27 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting visceral fat accumulation |
| AU2006300629B2 (en) * | 2005-09-22 | 2009-12-10 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting Visceral fat accumulation |
| WO2007034851A1 (en) * | 2005-09-22 | 2007-03-29 | Morinaga Milk Industry Co., Ltd. | Visceral fat accumulation inhibitor |
| KR100935813B1 (en) * | 2005-09-22 | 2010-01-08 | 모리나가 뉴교 가부시키가이샤 | Agent for inhibiting visceral fat accumulation |
| AU2006293136B2 (en) * | 2005-09-22 | 2010-01-14 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting visceral fat accumulation |
| KR100941015B1 (en) * | 2005-09-22 | 2010-02-05 | 모리나가 뉴교 가부시키가이샤 | Visceral fat accumulation inhibitor |
| US7846905B2 (en) | 2005-09-22 | 2010-12-07 | Morinaga Milk Industry Co., Ltd. | Agent for inhibiting visceral fat accumulation |
| EP1927360A4 (en) * | 2005-09-22 | 2010-09-29 | Morinaga Milk Industry Co Ltd | Visceral fat accumulation inhibitor |
| US7947669B2 (en) | 2005-09-30 | 2011-05-24 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
| US8236769B2 (en) * | 2005-09-30 | 2012-08-07 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
| US8575142B2 (en) | 2005-09-30 | 2013-11-05 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
| KR100967313B1 (en) * | 2005-09-30 | 2010-07-07 | 모리나가 뉴교 가부시키가이샤 | Agent for improving insulin resistance |
| AU2006300637C1 (en) * | 2005-09-30 | 2010-07-01 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
| KR100999317B1 (en) * | 2005-09-30 | 2010-12-09 | 모리나가 뉴교 가부시키가이샤 | Agent for improving insulin resistance |
| AU2006300637B2 (en) * | 2005-09-30 | 2009-12-10 | Morinaga Milk Industry Co., Ltd. | Agent for improving insulin resistance |
| WO2007043302A1 (en) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Agent for amelioration of insulin resistance |
| WO2007043306A1 (en) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Agent for amelioration of insulin resistance |
| KR100972952B1 (en) * | 2005-09-30 | 2010-07-30 | 모리나가 뉴교 가부시키가이샤 | Agent for improving insulin resistance |
| WO2007043305A1 (en) * | 2005-09-30 | 2007-04-19 | Morinaga Milk Industry Co., Ltd. | Agent for amelioration of insulin resistance |
| CN101233145B (en) * | 2005-09-30 | 2013-01-02 | 森永乳业株式会社 | Agent for amelioration of insulin resistance |
| WO2007060911A1 (en) | 2005-11-25 | 2007-05-31 | Morinaga Milk Industry Co., Ltd. | Aloe vera extract, process for production of aloe vera extract, and ameliorating agent for hyperglycemia |
| EP2206509A1 (en) | 2005-11-25 | 2010-07-14 | Morinaga Milk Industry Co., Ltd. | Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent |
| US8709512B2 (en) | 2005-11-25 | 2014-04-29 | Morinaga Milk Industry Co., Ltd. | Method for treating hyperglycemia |
| US8877265B2 (en) | 2005-11-25 | 2014-11-04 | Morinaga Milk Industry Co., Ltd. | Method of producing aloe vera extract |
| WO2020159038A1 (en) * | 2019-01-30 | 2020-08-06 | (주)메이준생활건강 | Pharmaceutical composition for preventing or treating obesity, containing extract of aloe vera, pseudocydonia sinensis and zea mays linne as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4499209B2 (en) | 2010-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
| JP2005060334A (en) | Anti-obesity agent having lipase inhibiting activity and antioxidation activity | |
| EP3326638A1 (en) | Pharmaceutical composition for preventing or treating il-6-mediated diseases comprisingrosa rugosa | |
| JP3768795B2 (en) | Xanthine oxidase inhibitor | |
| JPWO2005027892A1 (en) | Insulin early secretion enhancer | |
| JP2000319190A (en) | Prophylactic and improving agent for obesity | |
| JP2001131080A (en) | Material for suppressing increase of body weight obtained from hop | |
| JP4764518B1 (en) | Oral pore improver | |
| JP4456321B2 (en) | Lipase inhibitor | |
| JPH11180869A (en) | Blood lipid improving agent, cyclic amp phosphodiesterase inhibitor, drink and food, and skin preparation for external use | |
| JP5309292B2 (en) | Lipase inhibitor | |
| JP2006036787A (en) | Xanthine oxidase inhibitor | |
| KR101879685B1 (en) | Composition for anti-inflammation with nipa fruticans wurmb | |
| JP4325908B2 (en) | Lipolysis accelerator, skin external preparation and food and drink using the same | |
| JP2007070263A (en) | Composition for preventing diabetes mellitus | |
| JP2005082546A (en) | alpha-GLUCOSIDASE INHIBITOR | |
| JP2011111390A (en) | Hormone replacement therapy effect promoter | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JP2009007328A (en) | Antiallergic composition | |
| JP2021070670A (en) | Il-37 production enhancers | |
| WO2004019962A1 (en) | Hair growth stimulants for oral use | |
| JP2002080385A (en) | Metal deposition inhibitor | |
| JP2000116356A (en) | Antiallergic food and antiallergic agent | |
| JP5265177B2 (en) | Composition for improving bowel movements containing acacia bark | |
| JP2005239551A (en) | Hypotensive agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20041116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060412 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091027 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100413 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100415 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4499209 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140423 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |